Publication | Open Access

Rosiglitazone Reduces Plasma Levels of Inflammatory and Hemostatic Biomarkers and Improves Global Endothelial Function in Habitual Heavy Smokers Without Diabetes Mellitus or Metabolic Syndrome

Metabolic SyndromeCardiovascular DiseaseHemostatic BiomarkersMedicineLipid PeroxidationDiabetesPhysiologyGlobal Endothelial FunctionEndothelial DysfunctionVascular BiologyMicrovascular DysfunctionPharmacologyAtherosclerosisDyslipidemiaOxidative StressHealth Sciences